Valuation dashboard for Merck & Co., Inc. (MRK) with P/E 119.62, P/B 8.84, EV/EBITDA 31.91 and dividend yield 2.27%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes.
Analysis Summary
Merck & Co., Inc. reported revenue of $64.93B in the most recent fiscal year, growing at a 5-year CAGR of 9.4%. Net income reached $18.25B, with a 20.9% 5-year CAGR.
Trailing-twelve-month margins: gross margin 77.0%, operating margin 16.2%, net margin 3.6%.
At $149.52 (closing price, October 30, 2026), MRK trades at a P/E of 119.62 and an ROE of 5.10%. Market capitalisation stands at $368.9B, placing it among large-cap names.
Balance sheet quality for MRK: current ratio of 1.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 119.62 |
| Price / Book | 8.84 |
| EV / EBITDA | 31.91 |
| Dividend Yield | 2.27% |
Valuation Models
| DCF Fair Value | $171.99 |
| vs Current Price | +15.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $368.9B | 119.62 | 8.84 | 5.1% |
| AMGN | Amgen Inc. | $251.9B | 28.96 | 21.53 | 89.3% |
| GILD | Gilead Sciences, Inc. | $211.6B | 16.26 | -21.7% | |
| SNY | Sanofi | $106.9B | 23.29 | 1.32 | 5.5% |
| LLY | Eli Lilly and Company | $1.3T | 46.01 | 31.39 | 83.6% |
| JNJ | Johnson & Johnson | $657.7B | 41.42 | 8.37 | 19.6% |
| ABBV | AbbVie Inc. | $521.1B | 83.08 | -136.5% | |
| AZN | AstraZeneca PLC | $289.5B | 28.03 | 5.74 | 21.7% |
Price
| Price | $149.52 (closing price, October 30, 2026) |
| Market Cap | $368.9B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 5.10% |
| Return on Invested Capital | 5.36% |
| Return on Assets | 1.89% |
| Gross Margin | 76.95% |
| Operating Margin | 16.24% |
| Net Margin | 3.64% |
Related companies: AMGN · GILD · SNY · LLY · JNJ · ABBV · AZN · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of MRK: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks